The potential role for sphingolipids in neuropathogenesis of Alzheimer’s disease | Zendy

A. V. Alessenko | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The potential role for sphingolipids in neuropathogenesis of Alzheimer’s disease

Author(s) -

A. V. Alessenko

Publication year - 2013

Publication title -

biomeditsinskaya khimiya

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.192

H-Index - 15

eISSN - 2310-6972

pISSN - 2310-6905

DOI - 10.18097/pbmc20135901025

Subject(s) - sphingolipid , ceramide , sphingomyelin , sphingosine , disease , sphingosine 1 phosphate , pathogenesis , alzheimer's disease , biology , mechanism (biology) , neuroscience , medicine , microbiology and biotechnology , pharmacology , immunology , biochemistry , cholesterol , apoptosis , receptor , philosophy , epistemology

The review discusses the functional role of sphingolipids in the pathogenesis of Alzheimer's disease. Certain evidence exist that the imbalance of sphingolipids such as sphingomyelin, ceramide, sphingosine, sphingosine-1-phosphate and galactosylceramide in the brain of animals and humans, in the cerebrospinal fluid and blood plasma of patients with Alzheimer's disease play a crucial role in neuronal function by regulating growth, differentiation and cell death in CNS. Activation of sphingomyelinase, which leads to the accumulation of the proapoptotic agent, ceramide, can be considered as a new mechanism for AD and may be a prerequisite for the treatment of this disease by using drugs that inhibit sphingomyelinase activity. The role of sphingolipids as biomarkers for the diagnosis of the early stage of Alzheimer's disease and monitoring the effectiveness of treatment with new drugs is discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research